200 related articles for article (PubMed ID: 23579217)
1. Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness.
de Bock GH; Vermeulen KM; Jansen L; Oosterwijk JC; Siesling S; Dorrius MD; Feenstra T; Houssami N; Greuter MJ
Br J Cancer; 2013 Apr; 108(8):1579-86. PubMed ID: 23579217
[TBL] [Abstract][Full Text] [Related]
2. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
Phi XA; Greuter MJW; Obdeijn IM; Oosterwijk JC; Feenstra TL; Houssami N; de Bock GH
Breast; 2019 Jun; 45():82-88. PubMed ID: 30904701
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.
Cott Chubiz JE; Lee JM; Gilmore ME; Kong CY; Lowry KP; Halpern EF; McMahon PM; Ryan PD; Gazelle GS
Cancer; 2013 Mar; 119(6):1266-76. PubMed ID: 23184400
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
Plevritis SK; Kurian AW; Sigal BM; Daniel BL; Ikeda DM; Stockdale FE; Garber AM
JAMA; 2006 May; 295(20):2374-84. PubMed ID: 16720823
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.
Pataky R; Armstrong L; Chia S; Coldman AJ; Kim-Sing C; McGillivray B; Scott J; Wilson CM; Peacock S
BMC Cancer; 2013 Jul; 13():339. PubMed ID: 23837641
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.
Grann VR; Patel PR; Jacobson JS; Warner E; Heitjan DF; Ashby-Thompson M; Hershman DL; Neugut AI
Breast Cancer Res Treat; 2011 Feb; 125(3):837-47. PubMed ID: 20644999
[TBL] [Abstract][Full Text] [Related]
10. A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
Li Y; Arellano AR; Bare LA; Bender RA; Strom CM; Devlin JJ
Value Health; 2017 Apr; 20(4):547-555. PubMed ID: 28407996
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer.
Griebsch I; Brown J; Boggis C; Dixon A; Dixon M; Easton D; Eeles R; Evans DG; Gilbert FJ; Hawnaur J; Kessar P; Lakhani SR; Moss SM; Nerurkar A; Padhani AR; Pointon LJ; Potterton J; Thompson D; Turnbull LW; Walker LG; Warren R; Leach MO;
Br J Cancer; 2006 Oct; 95(7):801-10. PubMed ID: 17016484
[TBL] [Abstract][Full Text] [Related]
12. Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis.
Lowry KP; Lee JM; Kong CY; McMahon PM; Gilmore ME; Cott Chubiz JE; Pisano ED; Gatsonis C; Ryan PD; Ozanne EM; Gazelle GS
Cancer; 2012 Apr; 118(8):2021-30. PubMed ID: 21935911
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers.
Lee JM; McMahon PM; Kong CY; Kopans DB; Ryan PD; Ozanne EM; Halpern EF; Gazelle GS
Radiology; 2010 Mar; 254(3):793-800. PubMed ID: 20177093
[TBL] [Abstract][Full Text] [Related]
14. BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials.
Tilanus-Linthorst MM; Obdeijn IM; Hop WC; Causer PA; Leach MO; Warner E; Pointon L; Hill K; Klijn JG; Warren RM; Gilbert FJ
Clin Cancer Res; 2007 Dec; 13(24):7357-62. PubMed ID: 18094417
[TBL] [Abstract][Full Text] [Related]
15. Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk.
Tilanus-Linthorst MM; Lingsma HF; Evans DG; Thompson D; Kaas R; Manders P; van Asperen CJ; Adank M; Hooning MJ; Kwan Lim GE; Eeles R; Oosterwijk JC; Leach MO; Steyerberg EW
Int J Cancer; 2013 Jul; 133(1):156-63. PubMed ID: 23292943
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer screening, outside the population-screening program, of women from breast cancer families without proven BRCA1/BRCA2 mutations: a simulation study.
Jacobi CE; Nagelkerke NJ; van Houwelingen JH; de Bock GH
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):429-36. PubMed ID: 16537697
[TBL] [Abstract][Full Text] [Related]
17. Breast MRI screening for average-risk women: A monte carlo simulation cost-benefit analysis.
Mango VL; Goel A; Mema E; Kwak E; Ha R
J Magn Reson Imaging; 2019 Jun; 49(7):e216-e221. PubMed ID: 30632645
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of digital mammography screening before the age of 50 in The Netherlands.
Sankatsing VD; Heijnsdijk EA; van Luijt PA; van Ravesteyn NT; Fracheboud J; de Koning HJ
Int J Cancer; 2015 Oct; 137(8):1990-9. PubMed ID: 25895135
[TBL] [Abstract][Full Text] [Related]
19. Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation : A Comparative Modeling Study.
Yeh JM; Lowry KP; Schechter CB; Diller LR; Alagoz O; Armstrong GT; Hampton JM; Leisenring W; Liu Q; Mandelblatt JS; Miglioretti DL; Moskowitz CS; Oeffinger KC; Trentham-Dietz A; Stout NK
Ann Intern Med; 2020 Sep; 173(5):331-341. PubMed ID: 32628531
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of Universal BRCA1/2 Screening: Evidence-Based Decision Making.
Long EF; Ganz PA
JAMA Oncol; 2015 Dec; 1(9):1217-8. PubMed ID: 26335890
[No Abstract] [Full Text] [Related]
[Next] [New Search]